CD248 and ovarian cancer: To demonstrate the efficacy of BVC against ovarian cancer, researchers developed innovative mesoporous silica nanoparticles (MSN) coupled to tumour endothelial marker 1 (TEM1)/endosialin (Ab-/scFv).